Wisconsin Alzheimer's Disease Research center

威斯康星州阿尔茨海默病研究中心

• 批准号: 10601050
• 负责人: Sanjay Asthana
• 金额: $ 301.38万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-05-01 至 2024-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10601050
• 关键词: Adult; Aging; Alzheimer' s Disease; Alzheimer' s disease pathology; Alzheimer' s disease patient; Alzheimer' s disease related dementia; Alzheimer’s disease biomarker; Autopsy; Biochemical; Biological; Biological Markers; Blood; Brain; Caregiver support; Caring; Cells; Cerebrospinal Fluid; Clinical; Clinical Data; Cohort Studies; Collaborations; Communities; Competence; Consultations; County; DNA; DNA Repository; Data; Data Analyses; Data Collection; Data Set; Data Storage and Retrieval; Dementia; Development; Diagnosis; Disease; Disease Progression; Dissemination and Implementation; Doctor of Philosophy; Early Diagnosis; Early treatment; Education and Outreach; Enrollment; Ensure; Evaluation; Exercise; Faculty; Family; Funding; General Population; Genetic; Goals; Health Professional; Health Technology; Heterogeneity; Individual; Informatics; Infrastructure; Institution; International; Leadership; Link; Mentors; Mission; Modeling; Molecular; Native Americans; Nature; Neurobiology; Neurosciences; Oneida; Palliative Care; Participant; Pathologic; Pathology; Patient Care; Patient Recruitments; Patients; Postdoctoral Fellow; Prevention strategy; Process; Recording of previous events; Regulation; Research; Research Personnel; Research Project Grants; Research Support; Resources; Risk; Role; Safety; Sampling; Seminal; Standardization; Stem Cell Research; Symptoms; Techniques; Telemedicine; Training; Training Support; Underrepresented Minority; Underrepresented Populations; Wisconsin; Work; biomarker discovery; brain tissue; clinical diagnosis; clinical phenotype; clinical practice; collaborative environment; computerized tools; data management; education research; effective therapy; end of life; experience; genetic risk factor; genome wide association study; healthy aging; implementation research; improved; induced pluripotent stem cell; innovation; mHealth; middle age; multidisciplinary; neuroimaging; neuropathology; next generation; novel; outreach; outreach program; pre-clinical; programs; recruit; societal costs; synergism; treatment strategy; vascular risk factor; volunteer; web services

PROJECT SUMMARY - OVERALL The overall goal of the renewal of the Wisconsin Alzheimer's Disease Research Center (ADRC) is to support cutting-edge, innovative research on the pathobiology, early diagnosis and treatment of Alzheimer's disease (AD) and related illnesses. This goal will be accomplished by establishing a stimulating, interdisciplinary environment for collaborative research and providing invaluable clinical data, ante-mortem biospecimens, and autopsy brain tissue. Funded by NIA in 2009, the Wisconsin ADRC will support eight well-integrated Cores, including a new Care Research Core and Research Education Component (REC) that will support timely, innovative research, which will: 1) characterize preclinical biomarkers of AD and their role in predicting transition from preclinical to clinical stages of the disease; 2) investigate the neurobiology of AD; 3) identify novel vascular and genetic risk factors, linking them to the disease pathology and clinical phenotype; 4) incorporate contemporary biochemical and molecular techniques into clinical-pathologic cohort studies, including omics and next generation genetic sequencing; and 5) participate and facilitate the missions of other federal, state and local agency-supported aging and dementia research programs. The overall goals of the Center will be accomplished through coordinated activities of its eight Cores and the REC. The Administrative Core will provide scientific leadership to the ADRC as a whole. The Clinical Core will perform standardized evaluations and collect UDS and additional data on all research participants. It will work closely with the Outreach, Recruitment and Engagement (ORE) Core and the Inclusion of Underrepresented Groups (URG) Core to enhance enrollment of underrepresented minorities. The Data Management and Statistical (DMS) Core will continue to meet all data management, informatics, and statistical needs and support all the PC- and web-based services and processes. The Neuropathology Core will continue to provide neuropathologic diagnoses and process, store, and distribute antemortem biospecimens and postmortem brain tissue to support novel research in AD. The ORE Core will provide a broad-range of educational and outreach programs about AD and the Wisconsin ADRC missions to recruit research volunteers, especially those from URGs into the Clinical Core and other NIA-funded initiatives, such as ADCS, ADNI, NCRAD and GWAS studies. The URG Core will work closely with the ORE and Clinical Cores to enhance recruitment and retention of URG participants into the ADRC. The new Biomarker Core will support and provide access to resources in preclinical neuroimaging and cerebrospinal fluid (CSF) biomarkers of AD. The REC will coordinate closely with the Clinical, ORE, URG, Neuropathology and DMS Cores to provide state-of-the-art, competency-based training to postdoctoral fellows and early-stage faculty in all aspects of aging & dementia research. The new Care Research Core will provide novel expertise and resources to conduct innovative studies that will enhance patient care and change clinical practice.

项目概要-总体 更新威斯康星州阿尔茨海默病研究中心（ADRC）的总体目标是支持 关于阿尔茨海默病的病理生物学、早期诊断和治疗的前沿创新研究 (AD)及相关疾病。这一目标将通过建立一个激励，跨学科的 合作研究的环境，并提供宝贵的临床数据，生前生物标本， 尸检脑组织由NIA在2009年资助，威斯康星州ADRC将支持八个集成良好的核心， 包括一个新的护理研究核心和研究教育组成部分（REC），将支持及时， 创新研究，将：1）表征AD的临床前生物标志物及其在预测转变中的作用 从疾病的临床前到临床阶段; 2）研究AD的神经生物学; 3）鉴定新的血管 和遗传风险因素，将其与疾病病理学和临床表型联系起来; 4）将 现代生物化学和分子技术应用于临床病理学队列研究，包括组学和 下一代基因测序;和5）参与和促进其他联邦，州和地方的使命 机构支持的老龄化和痴呆症研究计划。中心的总体目标将得以实现 通过其八个核心和区域经济委员会的协调活动，行政核心将提供科学 对整个ADRC的领导。临床中心将进行标准化评价并收集UDS 以及所有研究参与者的额外数据。它将与外联、征聘和 参与（ORE）核心和包容代表性不足的群体（URG）核心，以提高入学率 代表性不足的少数民族。数据管理和统计核心将继续满足所有 数据管理、信息学和统计需求，并支持所有基于PC和Web的服务， 流程.神经病理学核心将继续提供神经病理学诊断和过程， 存储和分发生前生物标本和死后脑组织，以支持AD的新研究。 ORE核心将提供广泛的关于AD和 威斯康星州ADRC招募研究志愿者的任务，特别是那些从URG进入临床核心和 其他由NIA资助的倡议，如ADCS、ADNI、NCRAD和GWAS研究。城市资源小组核心将与 与ORE和临床核心合作，以加强URG参与者的招募和保留。的 新的生物标志物核心将支持并提供临床前神经成像和脑脊髓 AD的脑脊液（CSF）生物标志物。REC将与临床、ORE、URG、神经病理学和 DMS核心为博士后研究员和早期教师提供最先进的，基于能力的培训 参与衰老和痴呆症研究的各个方面。新的护理研究核心将提供新的专业知识， 资源进行创新的研究，这将提高病人护理和改变临床实践。

项目成果

A Quality Improvement Curriculum for Psychiatry Residents.

• DOI: 10.15766/mep_2374-8265.10870
• 发表时间: 2020-01-24
• 期刊: MedEdPORTAL : the journal of teaching and learning resources
• 作者: Reardon, Claudia L;Hafer, Roderick;Walaszek, Art
• 通讯作者: Walaszek, Art

Dementia in People with a Turkish Migration Background: Experiences and Utilization of Healthcare Services.

• DOI: 10.3233/jad-200184
• 发表时间: 2020
• 期刊: Journal of Alzheimer's disease : JAD
• 作者: Monsees J;Schmachtenberg T;Hoffmann W;Kind A;Gilmore-Bykovskyi A;Kim AJ;Thyrian JR
• 通讯作者: Thyrian JR

Validity Evidence for the Research Category, "Cognitively Unimpaired - Declining," as a Risk Marker for Mild Cognitive Impairment and Alzheimer's Disease.

• DOI: 10.3389/fnagi.2021.688478
• 发表时间: 2021
• 期刊: Frontiers in aging neuroscience
• 影响因子: 4.8
• 作者: Langhough Koscik R;Hermann BP;Allison S;Clark LR;Jonaitis EM;Mueller KD;Betthauser TJ;Christian BT;Du L;Okonkwo O;Birdsill A;Chin N;Gleason C;Johnson SC
• 通讯作者: Johnson SC

Dysphagia Profiles Among Inpatients with Dementia Referred for Swallow Evaluation.

• DOI: 10.3233/jad-220402
• 发表时间: 2022
• 期刊: JOURNAL OF ALZHEIMERS DISEASE
• 影响因子: 4
• 作者: Wang, Steven;Gustafson, Sara;Deckelman, Celia;Sampene, Emmanuel;Daggett, Sarah;Loosen, Julia;Robison, Raele;Pulia, Michael S.;Knigge, Molly;Thibeault, Susan;Gilmore-Bykovskyi, Andrea;Kind, Amy;Rogus-Pulia, Nicole
• 通讯作者: Rogus-Pulia, Nicole

Implications of preclinical Alzheimer's disease biomarker disclosure for US policy and society.

• DOI: 10.1002/dad2.12339
• 发表时间: 2022
• 期刊: Alzheimer's & dementia (Amsterdam, Netherlands)